Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yoowon Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Brain Disorders Research Center, Brain Science Research Division, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Multiple Sclerosis, Encephalomyelitis, Autoimmune, Experimental. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Dementia Research Center, National Research Foundation of Korea, Korea Institute of Science and Technology.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of the central nervous system (CNS), which leads to demyelination, axonal loss, and neurodegeneration. Increased oxidative stress and neurodegeneration have been implicated in all stages of MS, making neuroprotective therapeutics a promising strategy for its treatment. We previously have reported vinyl sulfones with antioxidative and anti-inflammatory properties that activate nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that induces the expression of cytoprotective genes against oxidative stress. In this study, we synthesized vinyl sulfoximine derivatives by modifying the core structure and determined therapeutic potential as Nrf2 activators. Among them, 10v effectively activated Nrf2 (EC50 = 83.5 nM) and exhibited favorable drug-like properties. 10v successfully induced expression of Nrf2-dependent antioxidant enzymes and suppressed lipopolysaccharide (LPS)-induced inflammatory responses in BV-2 microglial cells. We also confirmed that 10v effectively reversed disease progression and attenuated demyelination in an experimental autoimmune encephalitis (EAE) mouse model of MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Brain Disorders Research Center, Brain Science Research Division, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.
- Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
- Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Republic of Korea.
- Doping Control Center, KIST, Seoul 02792, Republic of Korea.
- Cureverse Co., Ltd., Seoul Biohub, Seoul 02455, Republic of Korea.
ORCID-Profile: Jaeick Lee, Ji Won Choi, Ki Duk Park
Förderung
- Korea Dementia Research Center
- National Research Foundation of Korea
- Korea Institute of Science and Technology
Zitieren
APA
Kim, Y., Kim, J., Kim, B., Kim, R., Kim, H. J., Lee, E. H., Kim, J., Park, J., Jeong, Y., Park, S. I., Kim, H., Kang, M., Lee, J., Bahn, Y. S., Choi, J. W., Park, J. H., & Park, K. D. (2024). Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01907
Vancouver
Kim Y, Kim J, Kim B, Kim R, Kim HJ, Lee EH, et al. Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01907
BibTeX
@article{Kim2024,
author = {Kim, Yoowon and Kim, Jaehwan and Kim, Byungeun and Kim, Rium and Kim, Hyeon Jeong and Lee, Elijah Hwejin and Kim, Jushin and Park, Jiwoo and Jeong, Yeeun and Park, Sang In and Kim, Hyemin and Kang, Minsik and Lee, Jaeick and Bahn, Yong-Sun and Choi, Ji Won and Park, Jong-Hyun and Park, Ki Duk},
title = {Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01907}
}
EUVIMED